Overview

• New guidance from Labor, Treasury, and HHS allows companies to offer optional, standalone fertility benefits similar to dental or vision coverage, without mandating participation or subsidies.
• The White House announced an agreement with EMD Serono to sell three IVF drugs—Gonal‑F, Ovidrel, and Cetrotide—at steeply reduced prices through the TrumpRx site, targeted to launch in early 2026.
• Officials and the company said eligible patients could see discounts of up to roughly 70% to 84% off list prices, with income-based eligibility up to 550% of the federal poverty level and estimated savings of about $1,200 to $2,200 per cycle.
• The fact sheet says state Medicaid programs will gain access to most‑favored‑nation pricing, EMD Serono will invest in U.S. manufacturing, and an additional fertility drug is being pursued for expedited FDA review.
• Analysts and advocates note medication discounts address only part of IVF expenses and that the benefit pathway is optional, raising questions about how broadly these changes will reduce total treatment costs.